Clinical trials: Cancer Colonic
Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8
- Trial name
- NCT05296681
- Testing
- NBT-NM108
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Howard S. Hochster, MD
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Primary Visceral Tumors of Any Histotype, Visceral Lesions
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy.
- Conditions
- Primary Visceral Tumors of Any Histotype, Visceral Lesions, Liver Cancer, Liver Metastasis Colon Cancer
- Trial name
- NCT06753136
- Testing
- percutaneous, laparoscopic or laparotomy lesion electrochemotherapy
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (Disorder)
Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy
People with inflammatory bowel disease (IBD), such as ulcerative colitis or Crohn's disease affecting the colon, have a higher risk of developing colon cancer over time.
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (Disorder), Crohns Disease, Colorectal Neoplasms
- Trial name
- NCT07089771
- Testing
- Virtual Chromoendoscopy, Dye-Based Chromoendoscopy
- Where
- Sweden
- Volunteers
- 480 people
- Sponsor
- Region Stockholm
Colorectal Neoplasms
Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance
From observational studies, it is know that the risk of developing colorectal cancer after polyp removal is lower if the patients adheres to surveillance recommendations.
- Trial name
- NCT06983639
- Testing
- Fecal occult blood testing, Colonoscopy
- Where
- Norway
- Volunteers
- 4,000 people
- Sponsor
- Sorlandet Hospital HF
Bladder Cancer, Breast Cancer
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
This clinical trial studies the effect of four different intervention components "tools" on body weight, nutrition, and physical activity in cancer survivors.
- Conditions
- Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer
- Trial name
- TTBF (NCT05056077)
- Testing
- Counseling, Educational Intervention, Health Education
- Where
- United States
- Volunteers
- 353 people
- Sponsor
- University of California, San Francisco
Colonic Neoplasms, Colorectal Neoplasms
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
- Trial name
- NCT00054912
- Testing
- EP2101
- Where
- 9 sites in United States
- Volunteers
- 18 people
- Sponsor
- Epimmune
Colorectal Neoplasms
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
Limited agents are optional after standard first and second line treatment for mCRC. Only Regorafenib and Fruquintinib are approved in China. PFS of these targeted drugs are not very long.
- Trial name
- NCT04683965
- Testing
- Pemetrexed, TAS-102, Bevacizumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
- Trial name
- NCT06657144
- Testing
- CHS-114, Toripalimab, 5 Fluorouracil
- Where
- 30 sites in United States, Taiwan
- Volunteers
- 154 people
- Sponsor
- Coherus Oncology, Inc.
Colorectal Neoplasms
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable).
- Trial name
- INVICTAN®-3 (NCT02776683)
- Testing
- BI 695502, Avastin
- Where
- 46 sites in United States, Japan and 2 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Patient Preference
Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.
This study is aiming to look into patients' treatment preferences and their socio economic background as well as the exploration of thought processes leading to these preferences.
- Trial name
- Pathos (NCT04925154)
- Testing
- The only intervention will be the information brochure that will be given after the first questionnaire.
- Where
- Canada
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting, Aged 70 or Older
MOST: Mediterranean Oncology Senior Tests
MOST is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "Adverse Events" predictive tool than the CGA (Comprehensive Geriatric…
- Trial name
- MOST (NCT02148731)
- Testing
- Frailty markers
- Where
- 8 sites in France
- Volunteers
- 180 people
- Sponsor
- Association Sud pour la Recherche en Oncogériatrie
Neoplasms, Gastric Cancer
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
The investigators seek to compare two techniques of removing pre-cancerous lesions from the colon. The investigators also will compare two solutions used during the procedure to determine if either solution allows for an improved…
- Trial name
- NCT01471756
- Testing
- Standard of Care Procedure as described in ARM
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
The Benefits of Deep Neuromuscular Block and Sugammadex in Laparoscopic Colorectal Surgery
Pneumoperitoneum, the use of carbon dioxide, presents some disadvantages, including a risk of hypercarbia and respiratory acidosis during surgery in the respiratory system, and of an increased mean arterial pressure and systemic…
- Trial name
- NCT02266056
- Testing
- Deep neuromuscular block using rocuronium and reversal with suggamadex, Moderate neuromuscular block using rocuronium and reversal with suggamadex
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Hand and Foot Syndrome, Erythrodysesthesia Syndrome
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of malignancy-related mortality. Capecitabine has been approved for the treatment of colorectal cancer as first-line therapy.
- Conditions
- Hand and Foot Syndrome, Erythrodysesthesia Syndrome, HFS, Colorectal Cancer
- Trial name
- HFS (NCT05327751)
- Testing
- Celecoxib 200mg, Capecitabine-based chemotherapy
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Colorectal Cancer, Liver Metastases
Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Evidence suggests that the addition of cetuximab or bevacizumab to doublet regimens could improve response rate and resectability rate of liver metastases and survival in colorectal liver metastases (CRLM).
- Trial name
- NCT04687631
- Testing
- mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Fudan University
Colonic Diseases, Adenocarcinoma
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer
Based on the astonishing high response rate in metastatic colorectal cancer in weekly high dose 5-FU and leucovorin, we will conduct a clinical trial to clarify the activity of this regimen in the adjuvant setting.
- Trial name
- NCT00201331
- Testing
- leucovorin+5-FU
- Where
- Taiwan
- Volunteers
- 162 people
- Sponsor
- National Health Research Institutes, Taiwan
Colonic Neoplasms
Establishing Effective Screening Methods for Diagnosing Hereditary Nonpolypoisis Colorectal Cancer
Correct identification of Lynch syndrome at the time of colorectal cancer presentation is important. We aim to find best ways to screen patients with colorectal cancer in Korea.
- Trial name
- NCT00516230
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Oesophageal Tumour, Gastric Tumours
DESI - Düsseldorfer ESD Study
Safety and effectiveness of endoscopic submucosal dissection
- Conditions
- Oesophageal Tumour, Gastric Tumours, Duodenal Tumours, Colon Tumours
- Trial name
- NCT06993402
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Torsten Beyna
Colon Cancer
Strength for Health
Despite a robust literature on the benefits of exercise for cancer survivors, most of the research to date falls in two primary areas - aerobic exercise and breast cancer survivors.
- Trial name
- NCT01882972
- Testing
- Exercise, Meditation
- Where
- United States
- Sponsor
- Loyola University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.